Table 3.

Discrimination metrics of the D:A:D, Framingham Hard CVD Risk Categories, and pooled cohort equation for coronary plaque by age strata, among HIV-infected men in the MACS, 2010–2013

			Sensitivity 95% CI				Specificity 95% CI			Area under the ROC curve

	N with plaque		D:A:D	FRS	PCE	N without plaque	D:A:D	FRS	PCE	D:A:D	FRS	PCE
≤ 50 years of age (n=201 CTA/n=248 CT)
CAC>0	88	≥ Moderate Risk Category	87.5% (78.7,93.6)	34.1% (24.3,45.0) ^***	48.9% (38.1,59.8) ^***	160	25.0% (18.5,32.4)	71.9% (64.2,78.7) ^***	58.1% (50.1,65.9) ^***	0.56	0.53	0.55
CAC>0	88	≥ High Risk Category	15.9% (9.0,25.2)	17.0% (9.9,26.6)	31.8% (22.3,42.6) ^***		86.9% (80.6,91.7)	86.9% (80.6,91.7)	78.1% (70.9,84.3) ^*
Any plaque on CTA	129	≥ Moderate Risk Category	85.3% (78.0,90.9)	33.3% (25.3,42.2) ^***	49.6% (40.7,58.5) ^***	72	37.5% (26.4,49.7)	79.2% (68.0,87.8) ^***	66.7% (54.6,77.3) ^***	0.64	0.57	0.59
Any plaque on CTA	129	≥ High Risk Category	17.1% (11.0,24.7)	16.3% (10.4,23.8)	30.2% (22.5,38.9) ^***		94.4% (86.4, 98.5)	94.4% (86.4, 98.5)	84.7% (74.3,92.1) ^*
Non-calcified plaque	97	≥ Moderate Risk Category	84.5% (75.8,91.1)	38.1% (28.5,48.6) ^***	53.6% (43.2,63.8) ^***	104	29.8% (21.2,39.6)	79.8% (70.8,87.0) ^***	65.4% (55.4,74.4) ^***	0.60	0.60	0.61
Non-calcified plaque	97	≥ High Risk Category	18.6% (11.4,27.7)	20.6% (13.1,30.0)	33.0% (23.8,43.3) ^**		92.3% (85.4,96.6)	95.2% (89.1, 98.4)	82.7% (74.0,89.4) ^**
Stenosis > 50%	18	≥ Moderate Risk Category	77.8% (52.4,93.6)	44.4% (21.5,69.2) ^*	44.4% (21.5,69.2) ^*	183	23.0% (17.1,29.7)	72.7% (65.6, 79.0) ^***	56.3% (48.8,63.6) ^***	0.54	0.61	0.52
Stenosis > 50%	18	≥ High Risk Category	22.2% (6.4,47.6)	33.3% (13.3,59.0)	33.3% (13.3,59.0)		88.0% (82.4,92.3)	89.6% (84.3,93.6)	76.0% 69.1,82.0) ^***

>50 years of age (n=244 CTA/n=351 CT)
CAC>0	227	≥ Moderate Risk Category	96.9% (93.7,98.8)	71.8% (65.5, 77.6) ^***	91.6% (87.2,94.9) ^**	124	5.6% (2.3,11.3)	45.2% (36.2,54.3) ^***	16.9% (10.8,24.7) ^**	0.56	0.56	0.57
CAC>0	227	≥ High Risk Category	40.5% (34.1,47.2)	24.7% (19.2,30.8) ^***	71.4% (65.0,77.2) ^***		69.4% (60.4,77.3)	74.2% (65.6,81.6)	41.1% (32.4,50.3) ^***
Any plaque on CTA	216	≥ Moderate Risk Category	95.4% (91.7,97.8)	62.5% (55.7,69.0) ^***	87.5% (82.3,91.6) ^***	28	3.6% (0.1,18.3)	46.4% (27.5,66.1) ^***	21.4% (8.3,41.0)	0.56	0.50	0.59
Any plaque on CTA	216	≥ High Risk Category	33.8% (27.5,40.5)	19.9% (14.8,25.9) ^***	66.7% (60.0,72.9) ^***		78.6% (59.0,91.7)	67.9% (47.6,84.1)	50.0% (30.6,69.4) ^*
Non-calcified plaque	183	≥ Moderate Risk Category	95.6% (91.6,98.1)	62.3% (54.8,69.3) ^***	86.9% (81.1,91.4) ^***	61	4.9% (1.0,13.7)	41.0% (28.6,54.3) ^***	14.8% (7.0,26.2) ^*	0.52	0.53	0.55
Non-calcified plaque	183	≥ High Risk Category	33.3% (26.6,40.7)	22.4% (16.6,29.1) ^**	67.2% (59.9,74.0) ^***		70.5% (57.4,81.5)	82.0% (70.0,90.6)	42.6% (30.0,55.9) ^**
Stenosis > 50%	57	≥ Moderate Risk Category	96.2% (90.6,99.0)	64.9% (51.1,77.1) ^***	87.7% (76.3,94.9) ^*	187	5.1% (2.1,10.2)	39.6% (32.5,47.0) ^***	13.9% (9.3,19.7) ^***	0.56	0.52	0.49
Stenosis > 50%	57	≥ High Risk Category	40.4% (27.6,54.2)	22.8% (12.7, 35.8) ^**	63.2% (49.3,75.6) ^**		70.1% (62.9, 76.5)	79.1% (72.6,84.7) ^*	34.8% (28.0,42.1) ^***

Difference in the sensitivity and specificity of the FRS and pooled cohort equation, each compared to the D:A:D was assessed using McNemar’s test;

p < 0.05,

^**

p < 0.01,

^***

p < 0.001